-
公开(公告)号：US20160145350A1
公开(公告)日：2016-05-26
申请号：US14994828
申请日：2016-01-13
Applicant: Bristol-Myers Squibb Company
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher
IPC: C07K16/40 , G01N33/573 , A61K39/395 , A61K47/48 , C07K16/30 , A61K45/06
CPC classification number: C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/573 , G01N2333/916
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
Abstract translation: 本发明提供分离的单克隆抗体，特别是人抗体，其以高亲和力结合人类分化簇73（CD73），并且抑制CD73的活性，并任选介导抗体依赖性CD73内化。 还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了使用本发明的抗体抑制表达CD73的肿瘤细胞生长的方法，包括治疗各种癌症的方法。
-
公开(公告)号：US08945553B2
公开(公告)日：2015-02-03
申请号：US13898544
申请日：2013-05-21
Applicant: Bristol-Myers Squibb Company
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
IPC: A61K39/395 , C07K16/46 , C07K16/24 , A61K39/00
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Abstract translation: 本发明涉及使用包含与IL-17A和IL-17F交叉反应的结合实体的双特异性抗体和结合IL-23p19的结合实体来拮抗IL-17A，IL-17F和IL-23的活性 。 本发明涉及新的双特异性抗体形式及其使用方法。
-
公开(公告)号：US11466092B2
公开(公告)日：2022-10-11
申请号：US16847130
申请日：2020-04-13
Applicant: Bristol-Myers Squibb Company
Inventor： Zhehong Cai , Indrani Chakraborty , Marie-Michelle Navarro Garcia , Thomas D. Kempe , Alan J. Korman , Alexander T. Kozhich , Hadia Lemar , Mark Maurer , Christina Maria Milburn , Michael Quigley , Xiang Shao , Mohan Srinivasan , Kent Thudium , Susan Chien-Szu Wong , Jochem Gokemeijer , Xi-Tao Wang , Han Chang , Patrick Guirnalda
IPC: A61K39/00 , A61K39/395 , G01N33/53 , C07K16/28 , C07K16/30 , A61P35/00 , G01N33/574
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US11352440B2
公开(公告)日：2022-06-07
申请号：US16117183
申请日：2018-08-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: A61K39/395 , C07K16/40 , C07K16/28 , C07K16/30 , G01N33/573 , A61K47/68 , A61K45/06 , G01N33/574 , A61K39/00
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
15.发明授权公开(公告)号：US11345752B2
公开(公告)日：2022-05-31
申请号：US16288245
申请日：2019-02-28
Applicant: Bristol-Myers Squibb Company
Inventor： Nils Lonberg , Mohan Srinivasan
Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
-
Patent Agency Ranking
公开(公告)号：US10653791B2
公开(公告)日：2020-05-19
申请号：US15520954
申请日：2015-11-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Mark J. Selby , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Michelle Minhua Han , Ming Lei , Liang Schweizer , Sandra V. Hatcher , Arvind Rajpal
IPC: C07K16/00 , C07K16/28 , C07K16/30 , A61K47/68 , A61K39/395
Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
公开(公告)号：US20190055321A1
公开(公告)日：2019-02-21
申请号：US16103654
申请日：2018-08-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley R. Krystek, JR. , Yong Zhang , Gregory D. Vite , Arvind Rajpal , Chetana Rao-Naik , Paul E. Morin , Mohan Srinivasan , Zheng Lin , Virginie Lafont , Alla Pritsker
IPC: C07K16/46
Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
-
公开(公告)号：US10167343B2
公开(公告)日：2019-01-01
申请号：US15432180
申请日：2017-02-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/30 , C07K16/40 , A61K39/00 , A61K39/395 , A61K45/06 , G01N33/573 , C07K16/28
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US09605080B2
公开(公告)日：2017-03-28
申请号：US14994828
申请日：2016-01-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/30 , C07K16/40 , A61K39/00 , A61K39/395 , A61K45/06 , G01N33/573
CPC classification number: C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/573 , G01N2333/916
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US20150099278A1
公开(公告)日：2015-04-09
申请号：US14576278
申请日：2014-12-19
Applicant: Bristol-Myers Squibb Company
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
IPC: C07K16/24
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Abstract translation: 本发明涉及使用包含与IL-17A和IL-17F交叉反应的结合实体的双特异性抗体和结合IL-23p19的结合实体来拮抗IL-17A，IL-17F和IL-23的活性 。 本发明涉及新的双特异性抗体形式及其使用方法。
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.036 seconds)
